2014 Notch Signaling in Development & Disease Gordon Research Conference/Seminar

2014 Notch Signaling 开发中

• 批准号: 8716109
• 负责人: Stephen C. Blacklow
• 金额: $ 0.9万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-10 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8716109
• 关键词: Academia; Address; Adult; Alagille Syndrome; Alzheimer' s Disease; Animal Model; Antibodies; Area; Attention; Biology; Boxing; CADASIL; Cancer Biology; Chronic; Clinical; Collaborations; Communication; Communities; Development; Developmental Biology; Developmental Cell Biology; Disease; Drosophila genus; Drug Industry; Dysostoses; Education; Environment; Event; Exposure to; Faculty; Future; Goals; Health; Heart Valves; Human; In Vitro; Industry; International; Lead; Leadership; Life; Location; Maine; Malignant Neoplasms; Mediator of activation protein; Memory; Mentors; Multiple Sclerosis; Muscular Dystrophies; Natural regeneration; Nature; Notch Signaling Pathway; Onset of illness; Organ; Organism; Outcome; Participant; Pathology; Pathway interactions; Peptide Hydrolases; Physics; Physiology; Play; Postdoctoral Fellow; Regulation; Reliance; Research; Research Personnel; Retina; Role; Scientist; Signal Pathway; Signal Transduction; Students; Syndrome; System; Technology; Therapeutic; Thinking; Time; Tissues; Toxic effect; Training; Travel; Work; abstracting; aortic valve disorder; base; body system; cancer initiation; cancer prevention; career; cell type; cohesion; college; cost; drug development; experience; frontier; gain of function; genome-wide; graduate student; human disease; in vivo; inhibitor/antagonist; interest; intestinal epithelium; loss of function; malformation; meetings; notch protein; novel; novel therapeutics; posters; programs; public health relevance; secretase; stem cell biology; success; symposium; tumor

DESCRIPTION (provided by applicant): The second Notch Signaling in Development, Regeneration & Disease meeting, to be held July 19-25, 2014 at Bates College, Maine, will address an unmet need in the scientific community, both academic and industrial. The broad and long-term goal of this conference is to enhance cross-disciplinary discussions and collaborations in this rapidly expanding field and to better address the myriad of mechanistic, developmental, organismal, clinical and therapeutic challenges met by practitioners in the field. The Notch signaling pathway is a central mediator of short-range inter-cellular communication in metazoans, under study since 1917 in Drosophila, in other model organisms since the 1980's, and in human health since 1991. More recent studies have established that alterations in Notch activity underlie several developmental syndromes (Alagille's Syndrome, Spondylocostal Dysostosis, aortic valve disease), adult onset diseases (CADASIL, various heart and valve malformations, muscular dystrophy, multiple sclerosis) and cause or contribute to cancer initiation, promotion or progression in a tissue-dependent manner. These pathologies reflect both loss of function (e.g., Alagille's, CADASIL) and gain of function (e.g., cancer). Because the Notch signaling pathway is unique in its reliance on proteases, in the paucity of signal modulators, and because it is repeatedly used in many organs throughout adult life, the road to chronic management of Notch signaling in disease is obscured by many untoward outcomes with available therapies. The main strategy currently practiced in anti-tumor campaigns is based on g-secretase inhibitors or antagonistic antibodies; however, due to their indiscriminate inhibition of Notch receptors in all organs, toxicity upon chronic administration remains a formidable challenge. Expanding the interest in this pathway beyond developmental biology and cancer prevention is the realization that a great hurdle in Alzheimer's disease research is the difficulty in developing reliable Notch-sparing g-secretase inhibitors capable of inhibiting APP cleavage. Solving these puzzles requires "outside the box" thinking. The Specific Aims for this interdisciplinary yet pathway-focused meeting is to bring together a diverse community of scientists working in every model organism and on nearly every organ system from academia, biotech and the pharmaceutical industry. The participants represent diverse approaches to study Notch function and regulation in normal and pathological contexts, which will further facilitate discovery and drug development efforts. The 40 projected speakers represent a blend of established world leaders with vast institutional memory and future leaders with exciting new findings to present. Significantly, the informal and confidential environment in Gordon conferences (GRCs), and the time provided for informal interactions, will create a forum in which cutting edge technologies, ideas and discoveries can be freely exchanged, stimulating new ideas. Most importantly, the combined GRC/GRS format excels in integrating students, postdocs and investigators wishing to enter a new field, such as the study of this important signaling pathway.

描述（由申请人提供）：将于2014年7月19日至25日在缅因州贝茨学院举行的第二次Notch信号转导发展，再生和疾病会议，将解决学术界和工业界未满足的需求。本次会议的广泛和长期目标是加强跨学科的讨论和合作，在这一迅速扩大的领域，并更好地解决无数的机械，发展，有机体，临床和治疗的挑战，在该领域的从业者遇到。Notch信号通路是后生动物中短距离细胞间通讯的中心介质，自1917年以来在果蝇中进行研究，自20世纪80年代以来在其他模式生物中进行研究，自1991年以来在人类健康中进行研究。最近的研究已经确定，Notch活性的改变是几种发育综合征（Alagille综合征、脊椎肋骨发育不全、主动脉瓣疾病）、成人发病疾病（CADASIL、各种心脏和瓣膜畸形、肌营养不良、多发性硬化）的基础，并且以组织依赖性方式引起或促成癌症的起始、促进或进展。这些病理反映了功能丧失（例如，Alagille的，CADASIL）和功能增益（例如，癌症）。由于Notch信号通路在其对蛋白酶的依赖性方面是独特的，缺乏信号调节剂，并且由于它在整个成年生活中在许多器官中重复使用，因此疾病中Notch信号传导的慢性管理之路被可用疗法的许多不利结果所掩盖。目前在抗肿瘤活动中实施的主要策略是基于g-分泌酶抑制剂或拮抗性抗体;然而，由于它们在所有器官中不加选择地抑制Notch受体，长期给药后的毒性仍然是一个巨大的挑战。将对这一途径的兴趣扩展到发育生物学和癌症预防之外是认识到阿尔茨海默病研究中的一个巨大障碍是难以开发能够抑制APP裂解的可靠的Notch-sparing g-分泌酶抑制剂。解决这些难题需要“跳出框框”的思维。这个跨学科但以路径为重点的会议的具体目标是汇集来自学术界，生物技术和制药行业的每个模式生物和几乎每个器官系统的不同科学家社区。参与者代表了在正常和病理背景下研究Notch功能和调节的多种方法，这将进一步促进发现和药物开发工作。预计的40位演讲者代表了具有丰富机构记忆的世界领导人和未来领导人的混合，他们将展示令人兴奋的新发现。重要的是，戈登会议（GRC）的非正式和保密环境，以及为非正式互动提供的时间，将创造一个论坛，在这个论坛上，前沿技术，想法和发现可以自由交流，激发新的想法。最重要的是，结合GRC/GRS格式擅长整合希望进入新领域的学生，博士后和研究人员，例如对这一重要信号通路的研究。